scholarly journals Association between serum level of advanced glycation end products and obstructive sleep apnea–hypopnea syndrome: a meta-analysis

2018 ◽  
Vol 46 (11) ◽  
pp. 4377-4385
Author(s):  
Xingyu Wu ◽  
Wensheng She ◽  
Xun Niu ◽  
Xiong Chen
Keyword(s):  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Serum Level ◽  
Advanced Glycation End Products ◽  
Meta Analysis ◽  
Advanced Glycation ◽  
Obstructive Sleep ◽  
Glycation End Products ◽  
End Products ◽  
Hypopnea Syndrome

Objective This meta-analysis was performed to assess the difference in the serum level of advanced glycation end products (AGEs) between patients with obstructive sleep apnea–hypopnea syndrome (OSAHS) and controls. Methods A systematic literature search was performed using PubMed, Elsevier, SCI, Wanfang, Weipu, and China National Knowledge Internet. Eligible studies that reported the serum AGE level in patients with OSAHS were identified by two reviewers. Review Manager version 5.2 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) and R version 3.10 ( www.r-project.org ) were employed for data synthesis. Results Five studies involving 670 subjects were identified. The meta-analysis showed that the mean serum AGE level in the OSAHS group was 0.98 mmol/L higher than those in the control group (95% confidence interval, 0.69–1.27). Conclusions This meta-analysis showed that the serum AGE level was elevated in patients with OSAHS. This finding suggests that AGEs may play an important role in insulin resistance in OSAHS and serve as a biomarker for patients with OSAHS with a high risk of type 2 diabetes mellitus.

scholarly journals Soluble Receptor for Advanced Glycation End Products (sRAGE) as a Biomarker of COPD 

2020 ◽  
Author(s):  
Katherine A. Pratte ◽  
Jeffery L. Curtis ◽  
Katerina Kechris ◽  
David Couper ◽  
Michael H. Cho ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Meta Analysis ◽  
Airflow Obstruction ◽  
Minor Allele ◽  
Soluble Receptor ◽  
Operating Characteristics ◽  
Advanced Glycation ◽  
Lung Density ◽  
Glycation End Products ◽  
End Products

Abstract Background:Soluble receptor for advanced glycation end products (sRAGE) is a proposed emphysema and airflow obstruction biomarker; however, previous publication have shown inconsistent associations and only one study has investigate the association between sRAGE and emphysema. No cohorts have examined the association between sRAGE and progressive decline of lung function. There have also been no evaluation of assay compatibility, receiver operating characteristics, and little examination of the effect of genetic variability in non-white population. This manuscript addresses these deficiencies and introduces novel data from Pittsburgh COPD SCCOR and as well as novel work on airflow obstruction. A meta-analysis is used to quantify sRAGE associations with clinical phenotypes.Methods: sRAGE was measured in four independent longitudinal cohorts on different analytic assays: COPDGene (n=1,443), SPIROMICS (n=1,623); ECLIPSE (n=2,349); Pittsburgh COPD SCCOR (n=399). We constructed adjusted linear mixed models to determine associations of sRAGE with baseline and follow up forced expiratory volume at one second (FEV1) and emphysema by quantitative high-resolution CT lung density at the 15th percentile (adjusted for total lung capacity).Results: Lower plasma or serum sRAGE values were associated with a COPD diagnosis (P<0.001), reduced FEV1 (P < 0.001), and emphysema severity (P<0.001). In an inverse-variance weighted meta-analysis, one SD lower log10-transformed sRAGE was associated with 105 ± 22 mL lower FEV1 and 4.14 ± 0.55 g/L lower adjusted lung density. After adjusting for covariates, lower sRAGE at baseline was associated with greater FEV1 decline and emphysema progression only in the ECLIPSE cohort. Non-Hispanic white subjects carrying the rs2070600 minor allele (A) and non-Hispanic African Americans carrying the rs2071288 minor allele (A) had lower sRAGE measurements compare to those with the major allele, but their emphysema-sRAGE regression slopes were similar. Conclusions: Lower blood sRAGE is associated with more severe airflow obstruction and emphysema, but associations with progression are inconsistent in the cohorts analyzed. In these cohorts, genotype influenced sRAGE measurements and strengthened variance modelling. Thus, genotype should be included in sRAGE evaluations.

Sign in / Sign up

Export Citation Format

Share Document